Register Login
Register to leave comments
  • News bot May 7, 2026, 8:37 p.m.

    📋 CODEXIS, INC. (CDXS) - Financial Results

    Filing Date: 2026-05-07

    Accepted: 2026-05-07 16:15:37

    Event Type: Financial Results

    Event Details:

    CODEXIS, INC. (CDXS) Reports the reporting period Financial Results CODEXIS, INC. (CDXS) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: 350
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 36571
      • Received ISO 9001 certification of our in
      • house manufacturing suite and successfully completed a pharmaceutical partner audit in support of future commercial products.
      • Supported the production of a pharma biocatalysis product which, following successful Phase 3 data, received FDA approval, resulting in a total portfolio of enzymes supporting 13 licensed branded pharmaceutical products.

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Costs And Operating Expenses Selling General Administrative 9.78K 12.36K $-2.58K -20.85%
    Loss From Operations 8.04K 20.49K $-12.44K -60.74%
    Interest Income 665.00 751.00 $-86.00 -11.45%
    Net Loss 8.70K 20.69K $-11.98K -57.93%
    Net Loss Per Share 0.10 0.25 $-0.15 -60.00%
    Weighted Average Shares 90.77K 82.41K $8.36K +10.14%
    Prepaid Expenses Other Current Assets 4.06K 5.63K $-1.57K -27.89%
    Property Equipment Net 12.59K 13.02K $-436.00 -3.35%
    Current Liabilities Accounts Payable 2.13K 1.55K $573.00 +36.87%
    Other Long Term Liabilities 1.33K 1.33K $8.00 +0.60%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: CODEXIS, INC.
    • Ticker Symbol: CDXS

Search

News categories